OBJECTIVETo explore the inhibition and molecular mechanism of icaritin (ICT) combined doxorubicin (DOX) on human osteosarcoma MG-63 cells in vitro.

METHODSThe control group, ICT groups (10, 20, 40, 80, and 160 µmol/L), DOX groups (1, 2, 4, 8, and 16 µg/mL), and combination groups (20 µmol/ L ICT +1 µg/mL DOX, 20 µmol/L ICT +2 µg/mL DOX, 20 µmol/L ICT +4 µg/mL DOX, 40 µmol/L ICT +1 µg/mL DOX, 40 µmol/L ICT +2 µg/mL DOX, 40 µmol/L ICT +4 µg/mL DOX, 80 µmol/L ICT +1 µg/mL DOX, 80 µmol/L ICT +2 µg/mL DOX, 80 µmol/L ICT +4 µg/mL DOX) were set up. Human osteosarcoma MG-63 cells were respectively cultured and their effects on morphological changes were observed using inverted phase contrast microscope after 24-and 48-h intervention. The cell proliferation inhibition rate of each group was de- termined using CCK-8, and IC50 calculated. The MG-63 apoptosis rate was detected using Annexin V-FITC/ PI double dye flow cytometry. Expression levels of bcl-2, caspase-3, and p21 were detected using RT-PCR.

RESULTSICT and DOX could obviously inhibit the proliferation of MG-63 cell. Along with ICT concentration increasing from 10 µmol/L to 160 µmol/L, the cell proliferation inhibition rate also increased gradually from 9.67% ± 3.62% to 89.18% ± 9.66%. The IC50 was 46.93 µmol/L and 3.87 µg/mL respectively. ICT and DOX could cause either early or late stage apoptosis, down-regulate Bcl-2 gene expression, and up-regulate gene expressions of Caspase-3 and p21 respectively (P < 0.05). Aforesaid changes were more obviously seen in combination groups than in lCT groups and DOX groups (P < 0.05).

CONCLUSIONCT combined DOX had additive or synergistic inhibition effect for the proliferation of osteosarcoma MG-63 cells, which might be related with regulating gene expressions of bcl-2, caspase-3, and p21.

Apoptosis ; Bone Neoplasms ; metabolism ; pathology ; Caspase 3 ; metabolism ; Cell Line, Tumor ; drug effects ; Cell Proliferation ; Cyclin-Dependent Kinase Inhibitor p21 ; metabolism ; Down-Regulation ; Doxorubicin ; pharmacology ; Drug Synergism ; Flavonoids ; pharmacology ; Humans ; Osteosarcoma ; metabolism ; pathology ; Proto-Oncogene Proteins c-bcl-2 ; metabolism

OBJECTIVEThe micronucleus test was applied to evaluate the genotoxicity of a new nanocomplex HA-PA66 root filling material in vitro.

METHODSThe dulbecco's modified eagle media(DMEM) extracts of the powder part and the mixture of the new nanomaterial were prepared separately. The V79 cell was used as the test cell and the mitomycin C(MMC) as the positive control. The MTT assay was employed in our study to evaluate the cytotoxic effect while the number of micronucleus was used as the criteria for the detection of genotoxocity.

RESULTSThe MTT values in test groups and negative group were not significantly different at different times (P > 0.05). The number of micronucleus in test groups (powder group: 6.1 +/- 1.1/1,000; complex group: 5.7 +/- 0.6/1,000) was similar to the negative control(5.3 +/- 0.8/1,000, P > 0.05), while they were significantly different to the positive control(123.9 +/- 8/1,000, P < 0.05).

CONCLUSIONThe new nanocomplex HA-PA66 root filling material showed no detectable cytotoxic and genotoxic effects in this study and was proved to be biocompatible.

Animals ; Biocompatible Materials ; toxicity ; Cricetinae ; Cricetulus ; Durapatite ; toxicity ; Micronucleus Tests ; methods ; Mutagenicity Tests ; methods ; Nanotechnology ; Nylons ; toxicity ; Root Canal Filling Materials ; toxicity

OBJECTIVETo investigate the biological effects of the new nano-hydroxyapatite/polyamide 66 biological composites (nHA-PA66) on the dental pulp cells.

METHODSAfter interaction with the nHA-PA66 eluate, the growth, proliferation, and function of the in vitro cultured human dental pulp cells were studied by cell culture technique, inverted phase-contrast microscope observation, MTT assay, flow cytometry, ALP activity assay and quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) analysis.

RESULTSThe cultured pulp cells grew well and showed no morphological variation. Moreover, this material had no negative effects on the proliferation, cell cycle, ALP activity and the expression of dentin sialophosphoprotein (DSPP) mRNA of the pulp cells.

CONCLUSIONAs a new nano-biomaterial, nHA-PA66 has good biocompatibility to the pulp cells, but no obvious bioactivity.

Biocompatible Materials ; Cell Line ; Cell Proliferation ; Cells, Cultured ; Dental Pulp ; Durapatite ; Humans ; Nylons

OBJECTIVETo analyze and find factors affecting the height of adjacent gingival papilla of maxillary central incisor single implant in human in order to promote the esthetic result of dental implants.

METHODSSixteen maxillary central incisor single implants of 16 patients and 30 sites of adjacent tissues and prosthesis were evaluated. Data on the height of adjacent gingival papilla of dental implant and relative factors were obtained from clinical parameters, photographs, research models, and X radiographs.

RESULTSThe mean and standard deviation of adjacent gingival papilla height of maxillary central incisor single implant were (4.01 +/- 1.85) mm. Statistical analysis revealed that factors affecting the height of adjacent gingival papilla of implant were as following from strong to weak: vertical distance between contact point and gingival margin, vertical distance between proximal bone level of natural tooth and implant abutment, vertical distance between proximal bone level of natural tooth and contact point, proximal protruding degree of crown, horizontal distance between abutment and root, length ratio of the crown and fixture, vertical distance between proximal bone level of implant and abutment, lip-side protruding degree of crown, probing depth.

CONCLUSIONSMultiple factors affected the height of adjacent gingival papilla of maxillary central incisor single implant in human.

Adult ; Aged ; Dental Implants, Single-Tooth ; Esthetics, Dental ; Female ; Gingiva ; anatomy & histology ; Humans ; Incisor ; surgery ; Linear Models ; Male ; Maxilla ; surgery ; Middle Aged ; Young Adult

OBJECTIVETo evaluate the antibacterial activity of nHA-PA66 on the predominant bacteria of infected root canal in vitro.

METHODSAgar diffusion method was the testing method. Porphyromonas gingivalis (P. gingivalis), Fusobacteria nucleatum (F. nucleatum) and Prevotalla intermedius (P. intermedius) were the tested bacteria. The powder and polymerized film of nHA-PA66 were the test mateials while the CCQ and filter paper as the control.

RESULTSnHA-PA66's powder showed good antebacterial effect on the P. gingivalis and P. intermedius, its film was weaker. Both of them had no effect on F. nucleatum.

CONCLUSIONnHA-PA66's antibacterial effect was not ideal, for better clinical results, some additives can be included.

Anti-Bacterial Agents ; Fusobacterium nucleatum ; Humans ; In Vitro Techniques ; Porphyromonas gingivalis ; Root Canal Therapy

OBJECTIVETo evaluate the biological effects of nano-hydroxyapatite/polyamide 66(nHA-PA66) on the growth and activity of osteoblast.

METHODSMTT assay was used to determine the growth of osteoblast, enzymatic measure was used to determine the activity of ALP and quantitative RT-PCR (QRT-PCR) to evaluate the changes of osteoclacin mRNA expression in osteoblasts treated by DMEM eluate of nHA-PA66.

RESULTSOsteoblasts of different test groups demonstrated relative proliferation rate ranging from 98% - 106% without dose-dependent effect. The ALP activity and osteocalcin mRNA expression were similar in test and control groups (P > 0.05).

CONCLUSIONnHA-PA66 has no negative effects on the osteoblast and its osteoblast-compatibility is proved.

Durapatite ; pharmacology ; Nylons ; pharmacology ; Osteoblasts ; drug effects ; Osteocalcin ; metabolism ; RNA, Messenger ; metabolism

Genotype ; Humans ; Seafood ; microbiology ; Vibrio Infections ; epidemiology ; microbiology ; Vibrio parahaemolyticus ; drug effects ; genetics ; pathogenicity

Objective To explore the reason and remedy on tumor patients' PICC misplacement.Methods The reason of 32 tumor patients' PICC misplacement were analyzed. The patients whose PICC misplaced were observed by X-ray,and then regulated to precava before remove the wire.Results PICC misplacement was much more observed in patients who was sixty years old or above than that of their younger counterpart (x2 =4.733,P ＜0.05).87.5％ of PICC misplacement were observed in the ipsilateral vein and less observed in right upper extremity ( x2 =7.552,P =0.006).The rate of PICC misplacement of cephalic vein,median cubital vein and basilic vein respectively were 15.7％,8.89％ and 8.12％.And there was no significant difference was detected in the gender,method and the location of cancer ( P ＞ 0.05 ).Finally,all the misplacement PICC were regulated to the right place.Conclusions Adept technology makes success,and more attention should pay to elderly patients.It is better to insert PICC in patient' s right upper extremity,especially basilic vein,and then median cubital vein.Utilize the X-ray to adjust patients position,and matching inspiration to adjust PICC' s location in order to avoid misplacement.

Objective To explore the significance of urine deoxypyridinoline to diagnosis on osseous metastasis of lung neoplasms.Methods.182 cases with lung carcinoma was divided into two groups.One group was case with osseous metastasis,the other group was case without osseous metastasis,uDPD/uCr, uCa/Cr,sCa and sAKP in two groups were respectively compared.Sensitivity and specificity of these indexes to diagnosis on osseous metastasis of lung cancer were also acalculated and compared.80 cases without osseous metastasis were follow-up for 6 months.Results The ratio of uDPD/uCr with osseous metastasis group[(12.35?2.65)nmol/mmol]was significantly higher than that of without osseous metastasis group [(7.76?2.11)nmol/mmol](t=2.46,P

BACKGROUNDGlycemic variability, an HbA1c-independent risk factor, has more deleterious effects than sustained hyperglycemia in the development of diabetic complications. This study analyzed the characteristics of glycemic variability in type 2 diabetes mellitus (T2DM) with HbA1c < 6.5% in duration of twice daily premixed insulin treatment and the effect of further treatment with acarbose.

METHODSEighty-six T2DM patients who used premixed insulin analogue (insulin aspart 30) twice daily and had HbA1c < 6.5% and 20 controlled subjects with normal glucose regulation (NGR) were monitored using the continuous glucose monitoring (CGM) system. The mean amplitude of glycemic excursions (MAGE), mean of daily differences (MODD) were used for assessing intra-day, inter-day glycemic variability. Hypoglycemia was defined as glucose level < 3.9 mmol/L for at least 15 minutes in CGM. According to reference values of MAGE, T2DM patients were classified into two groups: low-MAGE group with MAGE < 3.4 mmol/L (L-MAGE) and high-MAGE group with MAGE ≥ 3.4 mmol/L (H-MAGE). H-MAGE group received further treatment with acarbose for 2 weeks and was monitored a second time with CGM system.

RESULTSAfter first CGM, L-MAGE group had 41 cases, and H-MAGE group had 45 cases. The MAGE and MODD of T2DM group were all higher than those of subjects with NGR (P < 0.01). Twenty-four percent (n = 11) in H-MAGE group had a total of 13 hypoglycemic events, 10 of the 13 events occurred at night, meanwhile 5% (n = 2) in L-MAGE group had a total of 2 hypoglycemic events, which also occurred at night (hypoglycemic events: 24% vs. 5%, χ(2) = 6.40, P < 0.01). MAGE value was correlated with hypoglycemia value and 2-hour postprandial plasma glucose value (r = -0.32 and 0.26, respectively, P < 0.05). After further acarbose therapy and secondly CGM, MAGE and MODD values in H-MAGE group were all significantly decreased (40%, P < 0.01, and 15%, P < 0.05, respectively), but remained higher than in the subjects with NGR (P < 0.05); 2% (n = 1) had a total of 1 hypoglycemic event, incidence significantly decreased (2% vs. 24%, χ(2) = 9.61, P < 0.01).

CONCLUSIONSCGM system can detect the glycemic variability and asymptomatic hypoglycemic events of T2DM with well-controlled HbA1c in duration of insulin treatment. Combination therapy of premixed insulin twice daily with acarbose can flat glycemic variability and decrease hypoglycemic events.

Acarbose ; administration & dosage ; therapeutic use ; Adult ; Diabetes Mellitus, Type 2 ; blood ; drug therapy ; metabolism ; Female ; Glycated Hemoglobin A ; metabolism ; Humans ; Hypoglycemic Agents ; therapeutic use ; Insulin ; administration & dosage ; therapeutic use ; Male ; Middle Aged